Stereoisomerism
Rhodium
Molecular Structure
Palladium
Bay-Region, Polycyclic Aromatic Hydrocarbon
Alkylation
Inventions
Luminescent Measurements
Imidazoles
Heptanes
beta-Alanine
An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported.
Manubrium
2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-
Hazardous Substances
Safety
Coal Tar
A by-product of the destructive distillation of coal used as a topical antieczematic. It is an antipruritic and keratoplastic agent used also in the treatment of psoriasis and other skin conditions. Occupational exposure to soots, tars, and certain mineral oils is known to be carcinogenic according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985) (Merck Index, 11th ed).
Magnetic Resonance Spectroscopy
Dizocilpine Maleate
A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.
Dibenzocycloheptenes
Receptors, N-Methyl-D-Aspartate
A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity.
N-Methylaspartate
Carbazoles
Azabicyclo Compounds
Granisetron
Ondansetron
Heterocyclic Compounds
Encyclopedias as Topic
Chemistry, Organic
Heterocyclic Compounds, Bridged-Ring
Furans
Interleukin-12 is synthesized by mesangial cells and stimulates platelet-activating factor synthesis, cytoskeletal reorganization, and cell shape change. (1/947)
Preliminary studies indicate the involvement of interleukin (IL)-12 in experimental renal pathology. In the present study, we evaluated whether cultured glomerular mesangial cells are able to produce IL-12 and whether IL-12 may regulate some of their functions, including the cytoskeletal reorganization, the change in cell shape, and the production of platelet-activating factor (PAF). The results obtained indicate that pro-inflammatory stimuli, such as tumor necrosis factor-alpha and bacterial polysaccharides, induce the expression of IL-12 mRNA and the synthesis of the protein by cultured mesangial cells. Moreover, cultured mesangial cells were shown to bind IL-12 and to express the human low-affinity IL-12 beta1-chain receptor. When challenged with IL-12, mesangial cells produced PAF in a dose- and time-dependent manner and superoxide anions. No production of tumor necrosis factor-alpha and IL-8 was observed. Moreover, we demonstrate that IL-12 induced a delayed and sustained shape change of mesangial cells that reached its maximum between 90 and 120 minutes of incubation. The changes in cell shape occurred concomitantly with cytoskeletal rearrangements and may be consistent with cell contraction. As IL-12-dependent shape change of mesangial cells was concomitant with the synthesis of PAF, which is known to promote mesangial cell contraction, we investigated the role of PAF using two chemically different PAF receptor antagonists. Both antagonists inhibited almost completely the cell shape change induced by IL-12, whereas they were ineffective on angiotensin-II-induced cell shape change. In conclusion, our results suggest that mesangial cells can either produce IL-12 or be stimulated by this cytokine to synthesize PAF and to undergo shape changes compatible with cell contraction. (+info)Glutamate receptor signaling interplay modulates stress-sensitive mitogen-activated protein kinases and neuronal cell death. (2/947)
Glutamate receptors modulate multiple signaling pathways, several of which involve mitogen-activated protein (MAP) kinases, with subsequent physiological or pathological consequences. Here we report that stimulation of the N-methyl-D-aspartate (NMDA) receptor, using platelet-activating factor (PAF) as a messenger, activates MAP kinases, including c-Jun NH2-terminal kinase, p38, and extracellular signal-regulated kinase, in primary cultures of hippocampal neurons. Activation of the metabotropic glutamate receptor (mGluR) blocks this NMDA-signaling through PAF and MAP kinases, and the resultant cell death. Recombinant PAF-acetylhydrolase degrades PAF generated by NMDA-receptor activation; the hetrazepine BN50730 (an intracellular PAF receptor antagonist) also inhibits both NMDA-stimulated MAP kinases and neuronal cell death. The finding that the NMDA receptor-PAF-MAP kinase signaling pathway is attenuated by mGluR activation highlights the exquisite interplay between glutamate receptors in the decision making process between neuronal survival and death. (+info)Differences in the actions of some blockers of the calcium-activated potassium permeability in mammalian red cells. (3/947)
1. The actions of some inhibitors of the Ca2+-activated K+ permeability in mammalian red cells have been compared. 2. Block of the permeability was assessed from the reduction in the net loss of K+ that followed the application of the Ca2+ ionophore A23187 (2 microM) to rabbit red cells suspended at a haematocrit of 1% in a low potassium solution ([K]0 0.12-0.17 mM) at 37 degrees C. Net movement of K+ was measured using a K+-sensitive electrode placed in the suspension. 3. The concentrations (microM +/- s.d.) of the compounds tested causing 50% inhibition of K+ loss were: quinine, 37 +/- 3; cetiedil, 26 +/- 1; the cetiedil congeners UCL 1269, UCL 1274 and UCL 1495, approximately 150, 8.2 +/- 0.1, 0.92 +/- 0.03 respectively; clotrimazole, 1.2 +/- 0.1; nitrendipine, 3.6 +/- 0.5 and charybdotoxin, 0.015 +/- 0.002. 4. The characteristics of the block suggested that compounds could be placed in two groups. For one set (quinine, cetiedil, and the UCL congeners), the concentration-inhibition curves were steeper (Hill coefficient, nH, > or = 2.7) than for the other (clotrimazole, nitrendipine, charybdotoxin) for which nH approximately 1. 5. Compounds in the first set alone became less active on raising the concentration of K+ in the external solution to 5.4 mM. 6. The rate of K+ loss induced by A23187 slowed in the presence of high concentrations of cetiedil and its analogues, suggesting a use-dependent component to the inhibitory action. This was not seen with clotrimazole. 7. The blocking action of the cetiedil analogue UCL 1274 could not be overcome by an increase in external Ca2+ and its potency was unaltered when K+ loss was induced by the application of Pb2+ (10 microM) rather than by A23187. 8. These results, taken with the findings of others, suggest that agents that block the red cell Ca2+-activated K+ permeability can be placed in two groups with different mechanisms of action. The differences can be explained by supposing that clotrimazole and charybdotoxin act at the outer face of the channel whereas cetiedil and its congeners may block within it, either at or near the K+ binding site that determines the flow of K+. (+info)Endothelin antagonists block alpha1-adrenergic constriction of coronary arterioles. (4/947)
We have previously observed that intracoronary administration of the alpha1-adrenergic agonist phenylephrine (PE) over a period of minutes induced both an immediate and long-lasting (2 h) vasoconstriction of epicardial coronary arterioles. Because it is unlikely that alpha1-adrenergic constriction would persist for hours after removal of the agonist, this observation supports the view that another constrictor(s) is released during alpha1-adrenergic activation and induces the prolonged vasoconstriction. Therefore, we hypothesized that the prolonged microvascular constriction after PE is due to the production of endothelin (ET). We focused on ET not only because this peptide produces potent vasoconstriction but also because its vasoconstrictor action is characterized by a long duration. To test this hypothesis, the diameters of coronary arterioles (<222 micrometers) in the beating heart of pentobarbital-anesthetized dogs with stroboscopic intravital microscopy were measured during a 15-min intracoronary infusion of PE (1 microgram. kg-1 . min-1) and at 15-min intervals for a total of 120 min. All experiments were performed in the presence of beta-adrenergic blockade with propranolol. At 120 min, arterioles in the PE group were constricted (-23 +/- 9% change in diameter vs. baseline). Pretreatment with the ET-converting enzyme inhibitor phosphoramidon or the ETA-receptor antagonist FR-139317 prevented the PE-induced constriction at 120 min (-1 +/- 3 and -6 +/- 3%, respectively, P < 0.01 vs. PE). Pretreatment with the selective alpha1-adrenergic antagonist prazosin (Prz) also prevented the sustained constriction (0 +/- 2%, P < 0.01 vs. PE) but Prz given 60 min after PE infusion did not (-13 +/- 3%). In the aggregate, these results show that vasoconstriction of epicardial coronary arterioles via alpha1-adrenergic activation is blocked by an ET antagonist and an inhibitor of its production. From these data, we conclude that alpha1-adrenergic activation promotes the production and/or release of ET, which produces or facilitates microvascular constriction of epicardial canine coronary arterioles. (+info)Mechanism of weight gain suppressing effect of ER-40133, an angiotensin I converting enzyme inhibitor, in growing rats. (5/947)
Effects of ER-40133, an inhibitor of angiotensin converting enzyme (ACE), on weight gain and sodium and potassium balance were studied in growing SD male rats. Thirty-two animals (seven weeks of age) were divided into two groups; one received a standard diet containing 0.227% sodium and the other a low (0.065%) sodium diet. They were divided into four subgroups; one control group and three treated groups receiving 3, 10 or 30 mg/kg of ER-40133, by gavage, once a day for five consecutive days. Body weight gain (average of the standard and low sodium diet groups) was -32% in the 3 mg/kg group,-74% in 10 mg/kg group and -99% in 30 mg/kg group, when compared with the control group. There was a highly linear correlation between suppression of body weight gain and reduction in sodium and potassium retention for both groups of animals given the standard and low sodium diet. The reduced sodium retention, the primary effect of ACE inhibitors, accounted for about 30% of suppressed weight gain, and the reduced potassium retention, the secondary effect of sodium deficiency, could account for the rest about 70% of weight suppression by ER-40133. (+info)Endothelin receptor expression and pharmacology in human saphenous vein graft. (6/947)
1. We have investigated the expression and pharmacology of endothelin (ET) receptors in human aortocoronary saphenous vein grafts. 2. Subtype-selective ligands were used to autoradiographically identify ET(A) ([125I]-PD151242) and ET(B)([125I]-BQ3020) receptors. In graft saphenous vein ETA receptors predominated in the media, with few ET(B) receptors identified. Neither subtype was detected in the thickened neointima. 3. The ratio of medial ET(A):ET(B) receptors was 75%: 25% in both graft and control saphenous vein. 4. ET-1 contracted control (EC50 2.9 nM) and graft (EC50 4.5 nM) saphenous vein more potently than diseased coronary artery (EC50 25.5 nM). 5. In all three blood vessels ET-1 was 100 times more potent than ET-3 and three times more potent than sarafotoxin 6b (S6b). Little or no response was obtained in any vessel with the ET(B) agonist sarafotoxin 6c (S6c). 6. The ET(A) antagonist PD156707 (100 nM) blocked ET-1 responses in all three vessels with pKb values of approximately 8.0. 7. For individual graft veins the EC50 value for ET-1 and 'age' of graft in years showed a significant negative correlation. 8. In conclusion there is no alteration in ET receptor expression in the media of saphenous veins grafted into the coronary circulation compared to control veins. ETA receptors predominantly mediate the vasoconstrictor response to ET-1 in graft vein, with no apparent up-regulation of ET(B) receptors. The sensitivity of the graft vein to ET-1 increased with graft 'age', suggesting that these vessels may be particularly vulnerable to the increased plasma ET levels that are detected in patients with cardiovascular disease. (+info)Pharmacological and molecular biological evidence for ETA endothelin receptor subtype mediating mechanical responses in the detrusor smooth muscle of the human urinary bladder. (7/947)
The aim of this study was to characterize endothelin receptor subtypes of the detrusor muscle of the human urinary bladder. The receptor subtypes mediating endothelin (ET)-1-induced activity in the human detrusor smooth muscles have been characterized using isometric contraction and reverse transcription-polymerase chain reaction (RT-PCR). ET-1 (a non-selective ET receptor agonist; 10(-10) M to 10(-6) M) exhibited concentration-dependent contractions in human urinary bladder with a plateau at concentrations above 3x10(-7) M. Neither IRL1620 nor sarafotoxin S6c (both ETB-selective agonists; 10(-10) M to 10(-6) M) elicited contractile activity in the human urinary bladder detrusor smooth muscle. FR139317 (an ETA-selective antagonist; 10(-7) M to 10(-5) M) produced a marked shift to the right of the ET-1 concentration-response curve in human urinary bladder detrusor smooth muscle (from the Schild plot TpA2=7.96; slope=0.95). In contrast, RES701-1 (an ETB-selective antagonist; 10(-7) M to 10(-5) M) had no effect on the ET-1 concentration-response curve. RT-PCR revealed positive amplification of ETA receptor mRNA fragment, but not ETB. These results indicate that the ET-1-induced contractile effects of urinary bladder detrusor smooth muscle seem to be mediated mainly by the ETA receptor, not by the ETB receptor. (+info)Influence of platelet-activating factor on cerebral microcirculation in rats: part 1. Systemic application. (8/947)
BACKGROUND AND PURPOSE: Platelet-activating factor (PAF) has been demonstrated to have a mediator function in shock, with some of its deleterious effects being attributed to its influence on microcirculation. Systemic PAF concentrations as found in shock could also compromise the cerebral microcirculation. Our purpose in the present study was to examine the influence of systemically applied PAF on microvascular perfusion and leukocyte-endothelium interactions in cerebral microvessels. METHODS: A closed cranial window technique was used for intravital fluorescence microscopy of the brain surface. PAF was infused in concentrations of 10(-12), 10(-9), and 10(-6) mol/L into the carotid artery (5 mL/h for 20 min) of Sprague-Dawley rats (n=30). The selective PAF receptor antagonist WEB 2170BS (2 mg/kg body weight) was used to inhibit specific PAF effects. RESULTS: The number of leukocytes (cells/100 microm. min) rolling along or adhering at the venular endothelium increased following infusion of PAF 10(-6) mol/L from 7.7+/-2.5 to 24.4+/-8.9 (P<0.05) and from 1.9+/-0.5 to 6.9+/-2.2 (P<0.05), respectively, within 2 hours. Mean arterial pressure decreased from 92+/-22 mm Hg to 49+/-17 mm Hg (P<0.05). The lower concentrations of PAF were less effective to decrease mean arterial pressure but also induced leukocyte-endothelium interactions. The intravenous administration of WEB 2170BS 15 min before the infusion of PAF 10(-6) mol/L prevented both systemic hypotension and activation of leukocyte-endothelium interactions. CONCLUSIONS: Increased systemic blood levels of PAF as found during shock can not only cause systemic arterial hypotension but also induce leukocyte-endothelium interactions in cerebral venules. The activation of leukocytes was found to be independent of PAF-induced arterial hypotension. The specificity of these results is confirmed by the findings that WEB 2170BS could inhibit the PAF-induced systemic hypotension as well as the activation of leukocytes. (+info)
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies | Molecular Cancer...
BET bromodomain inhibition suppresses TH17-mediated pathology | JEM
PFI-1 free base | CAS#1403764-72-6 | BET bromodomain inhibitor | MedKoo Biosciences
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer |...
Most recent papers with the keyword Olaparib ovarian | Read by QxMD
Active Motif » JQ1 racemic (BET Bromodomain Inhibitor)
BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4...
Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor...
Publications [#330900] of Sayan Mukherjee
Plus it
JQ1, (+) - Chemietek
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. - NDM Research Building
Concise total synthesis of glucosepane | Science
BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis. - Department of Physiology, Anatomy and...
Plus it
RCSB PDB - 6SE4: Crystal Structure of the first bromodomain of human BRD4 in complex with (+)-JD1, an Organometallic BET...
Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of BET inhibitor JQ1 - refine.bio
Containing 10 FBS was added to the culture medium 6 h after transfection. | BET Bromodomain bet-bromodomain.comBET Bromodomain...
Building the Tools to Work with Glucosepane Cross-Links - Fight Aging!
Ally interconnected. To test this, we used STRING [13] to investigate whether | BET Bromodomain bet-bromodomain.comBET...
Therapeutic targeting of BET bromodomain proteins
YM155 reversible enzyme inhibition - Therapeutic targeting of BET bromodomain proteins
Semagacestat | PARP inhibitor BMN-673 targeting of the mutant p53-PARP-MCM chromatin axis
Plus it
James J. Kobie, Ph.D. - University of Rochester Medical Center
Gap Junction - Neuroscience - Signaling Pathways
Axial stereocontrol in tropos dibenz[c,e]azepines: the individual and cooperative effects of alkyl substituents - Organic &...
Brotizolam | The Merck Index Online
JCI -
Welcome
Besifloxacin ophthalmic (Besivance) Use During Pregnancy
ALZFORUM | NETWORKING FOR A CURE
Jifty-commit] r7365 - jifty/trunk/lib/Jifty/Web/Form
Idea and Web- Creating Lists Essay - 350 Words
西北农林科技大学动物医学院 - 周栋
View protein-drug interactions using Chime
Gentaur Molecular :Biovis \ BIX 01294 \ 1678-5
Effects of a myosin light chain kinase inhibitor on the optics and accommodation of the avian crystalline lens
BET bromodomain inhibitors Archives - Friedreichs Ataxia News
AZEPINE INHIBITORS OF JANUS KINASES - Patent application
Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. | Circulation...
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. - Department of Paediatrics
BROMODOMAIN INHIBITORS ARE POTENT EPIGENETIC REGULATORS OF CATABOLIC GENE EXPRESSION IN HUMAN OSTEOARTHRITIC CHONDROCYTES -...
Cancer Differentiating Ag… - Göteborgs universitet
To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban) - Full Text View -...
PAF receptor antagonists protected against PrP82-146 in | Open-i
OriGene - PTAFR (NM 001164721) Human ORF cDNA Clone
News | Australian Epigenetics Alliance
Most recent papers with the keyword Laura dawson | Read by QxMD
Life Archives - DIPG | The Marc Jr Foundation
Tumor Burden | Colorado PROFILES
Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes |...
IDDS (Integrated Drug Discovery Services)
The IN VIVO Blog: Deals of the Week: Ante Up For Antisense, Pharma Places Another Isis Bet
Stefan Zankl - Desktop-, Web- and mobile App- development
Stefan Zankl - Desktop-, Web- and mobile App- development
Scarpe Salomon Running Shoes- Salomon GCS Athletic Black Green White FubpcU Jq8VJQUE For Discount
Dial 911 Art Print by JQ Licensing
ش: Tips : Penjagaan Muka Sensitif & Bermasalah (Tolong Jaga Muka Wahai Perempuan Sekalian)
ش: Tips : Penjagaan Muka Sensitif & Bermasalah (Tolong Jaga Muka Wahai Perempuan Sekalian)
Fashion PULIS: Insta Scoop: Marjorie Barretto Proud of Claudia Barrettos Accomplishments in Career and School
Feeling Famous
SNOWFEST BIRDS
dissection tylenol or advil for cuts AE, Davies
Gastrik Angin
I am British and live in uk. My son was born in uk in 1981.
for programs to help pay for cymbalta BIOCHEMICAL
Heterocyclic compound
For azepine, benzazepine is the preferred name. Likewise, the compounds with two benzene rings fused to the central heterocycle ...
Carbamazepine
5H-dibenzo[b,f]azepine-5-carboxamide. CAS Number. *298-46-4 Y 85756-57-6 ...
5-HT2A receptor
2-alkyl-4-aryl-tetrahydro-pyrimido-azepines are subtype selective antagonists (35g: 60-fold).[63] ...
Azepane
Azepine "Hexamethyleneimine". Karsten Eller, Erhard Henkes, Roland Rossbacher, Hartmut Höke (2005). "Amines, Aliphatic". ...
1,2-Diazepine
Azepine Pubchem v t e. ...
Imipramine
... azepine (dibenzazepine), was first synthesized in 1899, but no pharmacological assessment of this compound or any substituted ... azepines; key synthons in syntheses of pharmaceutically active compounds". Journal of Heterocyclic Chemistry. 36 (1): 57-64. ...
Solenopsin
O'Hagan, David (1997). "Pyrrole, pyrrolidine pyridine, piperidine, azepine and tropane alkaloids". Natural Product Reports ( ...
Azomethine ylide
Nedolya, N. A.; Trofimov, B. A. (2013). "[1,7]-Electrocyclization reactions in the synthesis of azepine derivatives". Chemistry ...
Oxazepine
Azepine Benzazepines Diazepine Oxepin Borepin CR gas (dibenzoxazepine) v t e. ...
5-HT6 receptor
"Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists". Bioorganic & Medicinal Chemistry ...
Azonine
Azepine Pyrrole Cyclononatetraene (2Z,4Z,6Z,8Z)-Thionine Oxonine Somers, K. R. F.; Kryachko, E. S.; Ceulemans, A. (2004). " ...
José Barluenga
Synthesis of Azepines and Mechanistic NMR Studies". Chemistry: A European Journal. 2: 88-97. doi:10.1002/chem.19960020116. ...
Benzazepine
... s are heterocyclic chemical compounds consisting of a benzene ring fused to an azepine ring. Examples include: ...
Dibenzazepine
... (iminostilbene) is a chemical compound with two benzene rings fused to an azepine group. Benzazepine ...
Solar chemical
Various ketones, azepines and norbornadienes among other compounds, such as azobenzene and its derivatives, have been ...
5-HT2A receptor
LY-367,265 - dual 5-HT2A antagonist / SSRI with antidepressant effects 2-alkyl-4-aryl-tetrahydro-pyrimido-azepines are subtype ...
Divinylcyclopropane-cycloheptadiene rearrangement
9) Divinyl aziridines undergo a similar suite of reactions providing azepines or vinyl pyrrolines depending on the relative ...
Alfred Hassner
... as well as of larger ring heterocycles including azepines. Recently they studied TiCl 4 {\displaystyle _{4}} catalyzed ...
5-HT2C receptor agonist
... azepines as potent and selective 5-HT2C receptor agonists: Design, synthesis, and evaluation of PF-3246799 as a treatment for ...
Fluperlapine
... (NB 106-689), also known as fluoroperlapine, is a morphanthridine (11H-dibenzo[b,e]azepine ) atypical ...
CR gas
Molecular modeling studies on 11H-dibenz[b,e]azepine and dibenz[b,f][1,4]oxazepine derivatives as potent agonists of the human ...
PF-04479745
June 2014). "Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine ...
Controlled Drugs and Substances Act
... ethyl hexahydro-1-methyl-4-phenyl-azepine-4-carboxylate) and its salts Metethoheptazine (ethyl hexahydro-1,3-dimethyl-4- ...
Galantamine total synthesis
... galanthamine 9 the hydroxyl group is activated as the triflate and the amine group as the mesylate for intramolecular azepine ...
Ketipramine
It differs from imipramine in terms of chemical structure only by the addition of a ketone group, to the azepine ring, and is ...
C6H7N
The molecular formula C6H7N (molar mass: 93.12 g/mol) may refer to: Aniline Azepine Methylpyridines (picolines) 2- ...
Laniquidar
... azepine-3-carboxylate and its free base form has a chemical formula of C37H36N4O3 with a molecular weight of 584.720 g/mol. ...
Azepine
Azepines are unsaturated heterocycles of seven atoms, with a nitrogen replacing a carbon at one position. Azepane Benzazepines ...
Azepine - Wikipedia
Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone - Merck & Co., Inc.
... pyrrolidines and hexahydro-1H-azepines of the general structural formula: ##STR1## wherein R,sub,1,/ ... Thus, it is an object of the instant invention to describe the piperidine, pyrrolidine and hexahydro-1H-azepine compounds. It ... The instant invention is directed to certain piperidine, pyrrolidine and hexahydro-1H-azepine compounds which have the ability ... The novel piperidine, pyrrolidine and hexahydro-1H-azepine compounds of the instant invention are best described in the ...
10,11-Dihydro-dibenz[b,f]azepine-5-carbonyl chloride 97% | Sigma-Aldrich
Chemical Database: 1H-Azepine, hexahydro-1-(2-chloroethyl)-, hydrochloride (EnvironmentalChemistry.com)
This page contains information on the chemical 1H-Azepine, hexahydro-1-(2-chloroethyl)-, hydrochloride including: 12 synonyms/ ... 1H-Azepine, 1-(2-chloroethyl) hexahydro-, hydrochloride (8CI) (9CI) *1H-AZEPINE, HEXAHYDRO-1-(2-CHLOROETHYL)-*1H-Azepine, ... 1-(2-Chloroethyl)-hexahydro-1H-azepine hydrochloride*1-(2-Chloroethyl) hexahydro-1H-azepine*1-(2-Chloroethyl) hexamethylenimine ... 1H-Azepine, hexahydro-1-(2-chloroethyl)-, hydrochloride. Identifications. *CAS Number: 26487-67-2*Synonyms/Related:* ...
10,11-dihydro-5H-dibenz[b,f]azepine - Substance Information - ECHA
Hexahydro-1-(3-nitrobenzoyl)-1H-azepine (compound is called hexamethyleneimine m-nitro-benzoate in paper)
Axial stereocontrol in tropos dibenz[c,e]azepines: the individual and cooperative effects of alkyl substituents - Organic &...
... azepines, a class of secondary amine incorporating a centre-axis chirality relay, can be prepared from N-(2-bromobenzyl)-N-(1- ... 6,7-Dihydro-5H-dibenz[c,e]azepines, a class of secondary amine incorporating a centre-axis chirality relay, can be prepared ... Axial stereocontrol in tropos dibenz[c,e]azepines: the individual and cooperative effects of alkyl substituents S. M. C. ... Axial stereocontrol in tropos dibenz[c,e]azepines: the individual and cooperative effects of alkyl substituents ...
Ethyl hexahydro-1H-azepine-1-propionate | C11H21NO2 - PubChem
11. Synthesis of pyrimido[4,5-c]azepine- and pyrimido[4,5-c]oxepine.pdf | Enzyme Inhibitor | Amide
Synthesis of pyrimido[4,5-c]azepine- and pyrimido[4,5-c]oxepine.pdf - Free download as PDF File (.pdf), Text File (.txt) or ... continued in clinical trials presumably due to side effects such as azepines 3a/b (Fig. 1). Surprisingly, azepines of this type ... pling of azepine 26 with 30 and subsequent removal of the N- 7. Yan, R.; Vassar, R. Lancet Neurol. 2014, 13, 319.. Boc group ... The azepine and oxepine intermediates were utilized in the 2. Haass, C.; Selkoe, D. J. Nat. Rev. Mol. Cell Biol. 2007, 8, 101. ...
Application # 2017/0305935. Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative - Patents.com
There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory ... Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative Abstract. There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3- ... C. with a 1:1 mixture of THF and water (37.63 L) and ethyl 6-(4-nitrobenzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2- ... Ethyl 6-(4-nitrobenzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-car- boxylate ##STR00025## [0106] To a solution of 5- ...
108005-23-8, 1H-Pyridazino[3,4-b]azepine, 5,6,7,8-tetrahydro-3-(methylthio)-, CAS No 108005-23-8 1H-Pyridazino[3,4-b]azepine, 5...
... azepine, 5,6,7,8-tetrahydro-3-(methylthio)- ; physical and chemical property of 108005-23-8, 1H-Pyridazino[3,4-b]azepine, 5,6,7 ... 108005-23-8 1H-Pyridazino[3,4-b]azepine, 5,6,7,8-tetrahydro-3-(methylthio)-. product Name. 1H-Pyridazino[3,4-b]azepine, 5,6,7,8 ... the physical and chemical property of 108005-23-8, 1H-Pyridazino[3,4-b]azepine, 5,6,7,8-tetrahydro-3-(methylthio)- is provided ... CAS No: 108005-23-8, Chemical Name: 1H-Pyridazino[3,4-b]azepine, 5,6,7,8-tetrahydro-3-(methylthio)- ...
isoxazole azepine compound 3 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
7-Chloro-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride - Alfa Chemistry
We offer qualified products for 313673-94-8(7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]AZEPINE HYDROCHLORIDE),please inquire us for ... Home > Product > Heterocyclic Organic Compound > 7-Chloro-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride ... 7-Chloro-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride , CAS Number: 313673-94-8. ... 7-Chloro-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride ...
AZEPINE INHIBITORS OF JANUS KINASES - Patent application
... azepine trifluoroacetate [0237] A mixture of (6Z)-5H-dipyrido[2,3-b:4,3-f]azepine-5,6(11H)-dione 6-oxime (930 mg, 3.9 mmol), ... azepine A-80 ##STR00270## H 380 46 B Free Base 2-(3,5-dichlorophenyl)-3,8- dihydroimidazo[4,5-d]dipyrido[2,3- b:4,3-f]azepine ... azepine; 2-(5-cyclopropyl-3-methyl-1H-pyrazol-4-yl)-3,8-dihydroimidazo[4,5-d]dipyr- ido[2,3-b:4,3-f]azepine; 2-(2-chloro-6- ... azepine; 2-(1H-imidazol-2-yl)-3,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4,3-f]azep- ine; 2-(1-methyl-1H-imidazol-2-yl)-3,8- ...
Design, synthesis, and evaluation of azepine-based cryptophycin mimetics<...
Smith AB, Cho YS, Pettit G, Hirschmann R. Design, synthesis, and evaluation of azepine-based cryptophycin mimetics. Tetrahedron ... Design, synthesis, and evaluation of azepine-based cryptophycin mimetics. Amos B. Smith, Young Shin Cho, George Pettit, Ralph ... Smith, A. B., Cho, Y. S., Pettit, G., & Hirschmann, R. (2003). Design, synthesis, and evaluation of azepine-based cryptophycin ... Design, synthesis, and evaluation of azepine-based cryptophycin mimetics. In: Tetrahedron. 2003 ; Vol. 59, No. 35. pp. 6991- ...
12bet online-Liquid ammonia anhydrous|Soda ash|Ammonium chloride|Compound fertilizer|Hexahydro-1H-azepine--Jiangs
We are a research based and market oriented manufacturer. In a economic world today, we still believe honesty and quality are what values most in the business practices.Looking back, every step we make is deeply connected with the effortless hardwork of our employees, and your precious supports as well.
Reference Amb654518
| 3564-73-6
| 10,11-Dihydro-5H-dibenzo[b,f]azepine-5...
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages...
2,3,4,5-Tetrahydro-1H-benzo[b]azepine 1701-57-1 Chemical Safety Info Safety Info
10-Methoxy-5H-dibenzo[b,f]azepine 4698-11-7 H-NMR | C-NMR Spectral Analysis NMR Spectrum
A phase 3 trial of semagacestat for treatment of Alzheimer's disease
Azepane derivatives - Hoffmann-La Roche Inc.
Caprolactam 105-60-2, Information for Caprolactam 105-60-2, Suppliers of Caprolactam 105-60-2
Patent US5187277 - DL-3-[4-[4-(2-pyridyl)-1-piperazinyl]-butyl]-1,8,8-trimethyl-3-azabicyclo[(3 ... - Google Patents
Heterocyclic compound - Wikipedia
Clomipramine hydrochloride ≥98% (HPLC), powder | Sigma-Aldrich
MEDLINE - Resultado p gina 1
Does endothelin-1 play a role in the pathogenesis of cerebral vasospasm?
Dibenz6
- 6,7-Dihydro-5 H -dibenz[ c , e ]azepines, a class of secondary amine incorporating a centre-axis chirality relay, can be prepared from N -(2-bromobenzyl)- N -(1-arylalkyl)methanesulfonamides via Pd-catalysed intramolecular direct arylation, and methylated at C(7) via the 5,7- trans diastereoselective addition of methylmagnesium bromide to the derived N -benzylazepinium tetraphenylborate. (rsc.org)
- This invention relates to the use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the manufacture of various medicaments for treating neuropathic pain and for treating neurological disorders which involve both motor impairment and neuropathic pain. (patentsencyclopedia.com)
- 4. The method according to claim 3, wherein the 5H-dibenz/b,f/azepine-5-carboxamide derivative is eslicarbazepine acetate. (patentsencyclopedia.com)
- 11. The conjugate of 10-(3'-carboxypropyl)-5-(3'-dimethylaminopropyl)-10,11-dihydro-5H-dibenz[b,f]-azepine with glucose-6-phosphate dehydrogenase. (google.com)
- 12. The conjugate of 10-(3'-carboxypropyl)-5-(3'-dimethylaminopropyl)-10,11-dihydro-5H-dibenz[b,f]-azepine with a poly(amino acid) antigen. (google.com)
- Dimethylaminoethyl)-1H-dibenz[c,e]azepine-5,7-dione. (lehman.edu)
Compounds5
- The present invention is directed to certain novel compounds identified as substituted piperidines, pyrrolidines and hexahydro-1H-azepines of the general structural formula: ##STR1## wherein R 1 , R 4 , R 5 , A, X, Y and n are as defined herein. (freepatentsonline.com)
- It belongs to the piperazino-azepine group of compounds. (centerwatch.com)
- Compounds with BENZENE fused to AZEPINES. (harvard.edu)
- Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. (nih.gov)
- These are compounds with two benzene rings connected by an azepine ring. (drugbank.ca)
Analogs1
- Cleavage of APP by b-site APP cleaving enzyme-1 (BACE1) 29 nM) and no effect on total Ab production.11 In an effort to results in shedding of the APP ectodomain, and the remaining increase potency through conformational restriction, we sought membrane bound C-terminal fragment, C99, is further processed to prepare pyrimido[4,5-c]azepine analogs 2a/b (Fig. 1). (scribd.com)
Piperidines1
- Recent syntheses of azetidines, pyrrolidines, piperidines and azepines through cycloaddition or sigmatropic rearrangements of vinylaziridines are described. (mdpi.com)
Intermediates1
- In contrast, the corresponding benzo in cognition.8,9 A viable alternative to direct GS inhibition is GS [c]azepines 4 are common intermediates that have been widely modulation. (scribd.com)
Nitrogen3
- Azepines are unsaturated heterocycles of seven atoms, with a nitrogen replacing a carbon at one position. (wikipedia.org)
- A dibenzoazepine that is 5 H -dibenzo[ b , f ]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant. (ebi.ac.uk)
- Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom. (drugbank.ca)
Synthesis2
- Synthesis of pyrimido[4,5-c]azepine- and pyrim. (scribd.com)
- GS modulators (GSMs) reduce the level of longer, neu- used in the synthesis of benzazepine agents for the treatment of rotoxic Ab peptides (Ab42 and Ab43) by shifting the APP processing central nervous system disorders.12-15 In general, two methodolo- by c-secretase towards shorter isoforms (such as Ab37, Ab38) gies exist for the preparation of benzo[c]azepines 4 (Scheme 1). (scribd.com)
Substituents1
- Currently, a variety of solvents, substituents, temperatures, Lewis acids, and purification strategies are tested to increase the yield and reliability of azepine formation. (jmu.edu)
Chemical1
- The chemical name of APTIOM (eslicarbazepine acetate) is (S)-10-Acetoxy-10,11-dihydro-5Hdibenz[b,f]azepine-5-carboxamide. (rxlist.com)
Class1
- Given the potential of the cryptophycins for cancer therapy, we developed a new class of non-peptide peptidomimetic, designed to replace the 16-membered macrolide ring with a 7-membered azepine ring for attachment of the cryptophycin side chains with the required spatial orientation to mimic the conformation of the relevant region of the natural product. (elsevier.com)
Promote1
- Subsequently, various Lewis acids were used to promote the rearrangement of the aminal into the azepine. (jmu.edu)
Drug discovery1
- Azepine Ltd. is the reliable chemical supplier for your research and drug discovery projects. (worldofchemicals.com)